[1] Adverseeffects of anticancer agents that target the VEGF pathway,Nat Rev Clin Oncol. 2009,6(8):465-477.

[2] 高血压与安罗替尼治疗二线及以上晚期食管鳞癌的疗效相关性分析, 2019 CSCO.

[3] Evaluation ofhypertension and hand-foot syndrome as markers of anlotinib efficacy inadvanced soft tissue sarcoma.2018 ESMO，abs 1633.

[4] Retrospective analysis ofbevacizumab-induced hypertension and clinical outcome in patients withcolorectal cancer and lung cancer，Cancer Medicine, 2016, 5(7):1381.

[5] Correlation of bevacizumab-induced hypertension andoutcomes of metastatic colorectal cancer patients treated with bevacizumab: asystematic review and meta-analysis，World J Surg Oncol,2013, 28,11:306.

[6] Usefulness of bevacizumab-induced hypertension in patients with metastatic colorectal cancer:an updated meta-analysis,Aging (Albany NY). 2018,10(6):1424.

[7] Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in  second-line treatment of gastric cancer.Gastric Cancer,2018,21(2):276 .

[8] Tolerability of nintedanib (BIBF 1120) incombination with docetaxel: a phase 1 study in Japanese patients with previouslytreated non-small-cell lung cancer.J Thorac Oncol 2015,10(2):346-352.